“The opening of this new center is a testament to the growth we have seen with cell and gene therapies and the promise of their potential to impact patients,” said Fran Gregory, VP, Emerging Therapies. “Our investments in this space will have the potential to impact thousands of patients with rare diseases for which there are currently no or limited treatment options. We are excited to expand our capabilities to deliver treatments to patients that need them the most.”
The new center features deep-frozen storage, temperature-controlled shipping capabilities, and collaboration areas. It will also offer Advanced Therapy Connect, a unified ordering portal, and market access strategy consulting services.
“Many advanced therapies require specialized handling and temperature controls through the storage and shipping process to ensure their quality, safety and efficacy,” said Joel Wayment, VP/GM, 3PL Services and Packaging Solutions. “The Advanced Therapy Innovation Center will allow us to further support manufacturers – so that patients receive the treatments that they need when they need them.”
This investment positions Cardinal Health as a leading provider of logistics solutions for the cell and gene therapy industry, helping to ensure that patients receive these critical treatments in a timely and efficient manner.
https://www.contractpharma.com/contents/view_breaking-news/2024-08-28/cardinal-health-opens-new-advanced-therapy-center/9769

Check out our mRNA service to expedite your vaccine research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

AAV Packaging Services
READ MORE

Off-the-Shelf AAV Products
READ MORE